Bayer drug shown to slow diabetic kidney disease

Bayer's BAYGn.DE finerenone drug slowed the progression of diabetic kidney disease in a late stage clinical trial, underscoring the company's hopes for the drug to generate at least 1 billion euros ($1.2 billion) in annual sales.